A high incidence ofprolonged stabilization of serum prostate-specific antigen (PSA) was observedin phase II clinical study, where patients with advances prostate cancer whohad no symptoms of metastasis were treated with troglitazone (800 mg/dayorally). The gene discussed is KLK3; the disease is prostate carcinoma.